Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies

Journal of Nuclear Medicine

Volumn 46, Issue 7, 2005, Pages 1109-1118

  Koch, Walter ^a   Radau, Perry E ^b   Hamann, Christine ^a   Tatsch, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Automatic data processing; Dopamine transporter; FP CIT; Quantitative evaluation

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; N (3 FLUOROPROPYL)NORDIPRENORPHINE; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; SLC6A3 PROTEIN, HUMAN; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOMATION; BRAIN REGION; COMPUTER PROGRAM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING; DRUG DEVELOPMENT; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL INFORMATION; ALGORITHM; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; FEMALE; IMAGE SUBTRACTION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PARKINSON DISEASE; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ADULT; AGED; ALGORITHMS; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; OBSERVER VARIATION; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFTWARE; SUBTRACTION TECHNIQUE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 23844493148     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 123I]Beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-1167.
2. Eberl S, Kanno I, Fulton RR, Ryan A, Hutton BF, Fulham MJ. Automated interstudy image registration technique for SPECT and PET. J Nucl Med. 1996;37:137-145.
3. Chang DJ, Zubal IG, Gottschalk C, et al. Comparison of statistical parametric mapping and SPECT difference imaging in patients with temporal lobe epilepsy. Epilepsia. 2002;43:68-74.
4. Gispert JD, Pascau J, Reig S, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19: 601-612.
5. Van Laere KJ, Warwick J, Versijpt J, et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med. 2002;43:458-469.
6. Sipila O, Nikkinen P, Pohjonen H, et al. Accuracy of a registration procedure for brain SPET and MRI phantom and simulation studies. Nucl Med Commun. 1997;18:517-526.
7. Radau PE, Slomka PJ, Julin P, Svensson L, Wahlund LO. Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Med Phys. 2001;28:1660-1668.
8. Hill DL, Maurer CR Jr, Studholme C, Fitzpatrick JM, Hawkes DJ. Correcting scaling errors in tomographic images using a nine degree of freedom registration algorithm. J Comput Assist Tomogr. 1998;22:317-323.
9. Studholme C, Hawkes DJ, Hill DL. A normalized entropy measure for multimodality image alignment. In: Hansen KM, ed. Proceedings of SPIE: Medical Imaging 1998-Image Processing. Bellingham, WA: SPIE; 1998:132-143.
10. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220-227.
11. 2 transporter ligands. Eur J Nucl Med Mol Imaging. 2002; 29:BP30-BP35.
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
13. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT technical and interobserver variability. J Nucl Med. 1993;34:2076-2084.
14. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38:1453-1459.
15. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
16. Oertel WH, Gerstner A, Hoffken H, Dodel RC, Eggert KM, Moller JC. Role of dopamine transporter SPECT for the practitioner and the general neurologist. Mov Disord. 2003;18(suppl 7):S9-S15.
17. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord. 2003;18(suppl 7):S16-S21.
18. Marshall V, Grosset DG. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord. 2003;18(suppl 7):S22-S27.
19. 123I]-FP-CIT Study Group. Mov Disord. 2000;15:503-510.
20. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721-725.
21. 123I] beta-CIT SPECT. J Neural Transm. 2000;107:543-552.
22. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism a longitudinal beta-CIT SPECT study. Mov Disord. 2002;17:45-53.
23. 123I]IPT binding to the presynaptic dopamine transporter variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med. 2000;27:1809-1812.
24. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and position emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys. 1997;24:25-35.
25. Sychra JJ, Pavel DG, Chen Y, Jani A. The accuracy of SPECT brain activation images propagation of registration errors. Med Phys. 1994;21:1927-1932.
26. Slomka PJ, Radau P, Hurwitz GA, Dey D. Automated three-dimensional quantification of myocardial perfusion and brain SPECT. Comput Med Imaging Graph. 2001;25:153-164.
27. Van Laere K, Koole M, D'Asseler Y, et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med. 2001;42:361-375.
28. 123I]PE2I. Neuroimage. 1999;9:108-116.
29. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-n-omega-fluoropropyl- 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39:1143-1148.
30. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884.
31. 99mTc- TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207-213.
32. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996;37: 222-228.
33. 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med. 2004;18:609-616.
34. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002; 125:861-870.
35. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
36. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. 2002; 73:529-534.
37. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol. 1994;36:237-239.
38. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990;27:157-161.
39. 123I-FP-CIT SPECT comparability of modern SPECT systems. J Nucl Med. 2003;44:839-845.
40. Hamann CS, Koch W, Radau PE, Tatsch K. Automated evaluation of dopamine D2 receptor SPECT studies benefit in clinical routine [abstract]? J Nucl Med. 2003;44(suppl):261P-262P.